Collaboration between our industry and healthcare professionals, healthcare organizations and patient organizations benefits patients. It is a relationship that has delivered numerous innovative medicines and treatments and changed the way many diseases impact our lives.
Our industry, healthcare professionals, healthcare organizations and patient organizations collaborate in a range of activities in the fields of clinical research, sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. Bringing greater transparency to this already well-regulated, vital relationship is about building the basis for collaboration in the future.
Society has increasingly high expectations for transparency, in particular in the healthcare sector. At Takeda, we want to ensure we meet those expectations going forward.
Takeda is also participating in this initiative for the following reasons:
The disclosure of transfers of value to Belgian healthcare professionals, healthcare organizations and patient organizations is regulated by the Belgian Sunshine Act of 2017. All pharmaceutical and medical devices companies use www.betransparent.be as a common platform to disclose their financial remunerations and the contributions to the costs of scientific meetings offered to healthcare professionals, healthcare organizations and patient organizations.
More information is available at http://www.betransparent.be/
For Luxembourg, all companies that are a member of APL (Association Pharmaceutique Luxembourgeoise) must disclose their financial remunerations and contributions to the costs of scientific meetings offered to healthcare professionals, healthcare organizations and patient organizations.